Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Operating Income (2020 - 2025)

Historic Operating Income for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to -$15.1 million.

  • Barinthus Biotherapeutics' Operating Income fell 6061.83% to -$15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.4 million, marking a year-over-year decrease of 2758.64%. This contributed to the annual value of -$68.0 million for FY2024, which is 1900.04% up from last year.
  • As of Q3 2025, Barinthus Biotherapeutics' Operating Income stood at -$15.1 million, which was down 6061.83% from -$23.3 million recorded in Q2 2025.
  • In the past 5 years, Barinthus Biotherapeutics' Operating Income ranged from a high of $13.2 million in Q2 2022 and a low of -$26.3 million during Q2 2023
  • Its 5-year average for Operating Income is -$13.7 million, with a median of -$16.8 million in 2021.
  • As far as peak fluctuations go, Barinthus Biotherapeutics' Operating Income skyrocketed by 23070.81% in 2022, and later plummeted by 338501.53% in 2023.
  • Quarter analysis of 5 years shows Barinthus Biotherapeutics' Operating Income stood at -$16.7 million in 2021, then crashed by 50.55% to -$25.1 million in 2022, then increased by 20.34% to -$20.0 million in 2023, then dropped by 17.02% to -$23.4 million in 2024, then skyrocketed by 35.59% to -$15.1 million in 2025.
  • Its last three reported values are -$15.1 million in Q3 2025, -$23.3 million for Q2 2025, and -$20.6 million during Q1 2025.